Showing 15 posts of 89 posts found.


Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib

June 9, 2023
Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical

Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …


NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …


NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia

November 10, 2020
Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax

NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …


AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients

June 15, 2020
Sales and Marketing AbbVie, leukaemia

AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …


Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020

June 1, 2020
Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab

Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …


Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

May 29, 2020
Medical Communications Alzheimer's, leukaemia

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …


AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod

April 22, 2020
Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia

AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …


Researchers modify T-cells to identify and target multiple sites on leukaemia cells

April 1, 2020
Research and Development Cancer, Cancers, children cancer, leukaemia

Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019
Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …

Sanofi acquires biotech firm Synthorx for $2.5 billion

December 9, 2019
Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia

Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …

FDA approves AstraZeneca’s Calquence in chronic lymphoma

November 25, 2019
Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology

The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …

European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia

October 28, 2019
Sales and Marketing Astellas, Xospata, leukaemia, pharma

Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …


Janssen’s Imbruvica shows superiority in Phase 3 trials

June 4, 2019
Manufacturing and Production Janssen, imbruvia, leukaemia, pharma, phase 3, trial

Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab. In the …

FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia

May 16, 2019
Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma

Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …


Researchers find Achilles’ heel protein in leukaemia

April 26, 2019
Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia

An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …

Latest content